Targeting mitochondrial RNA modifications in aggressive leukemia
Official title: Targeting mitochondrial RNA methylation in high-risk acute myeloid leukemia
Funded at Beckman Research Institute/city of Hope · NIH-11024644 · Data updated 2026-11-12
This study is looking at how changes in mitochondrial RNA might affect leukemia stem cells in people with acute myeloid leukemia (AML), with the goal of finding new ways to treat this tough-to-treat blood cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | December 10, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $487,542 |
| NIH project number | 1R01CA296394-01 |
| Project ID | NIH-11024644 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute myeloid leukemia, particularly those with MLL rearrangements or FLT3 internal tandem duplications.
✕Less likely to help
Patients with other types of leukemia or those whose AML does not involve the specific genetic alterations being studied may not benefit from this research.
What this research studies
This research focuses on acute myeloid leukemia (AML), a severe blood cancer that often remains untreatable. The study aims to understand how modifications to mitochondrial RNA can influence the behavior of leukemia stem cells, which are responsible for the disease's initiation and relapse. By investigating the role of mitochondrial metabolism and RNA modifications, the researchers hope to identify new therapeutic strategies to eliminate these cancerous cells. The approach includes analyzing large datasets to pinpoint specific vulnerabilities in AML that can be targeted for treatment.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively target and eliminate leukemia stem cells, potentially improving outcomes for AML patients.
How similar studies have gone: Previous research has shown promise in targeting RNA modifications in cancer, suggesting that this approach could be effective, although the specific focus on mitochondrial RNA in AML is relatively novel.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Su, Rui — Beckman Research Institute/city of Hope
- Study coordinator: Su, Rui
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.